Meta-Analysis of CHADS2 versus CHA2DS2-VASc for Predicting Stroke and Thromboembolism in Atrial Fibrillation Patients Independent of Anticoagulation
Open Access
- 1 February 2015
- journal article
- research article
- Published by Texas Heart Institute Journal in Texas Heart Institute Journal
- Vol. 42 (1), 6-15
- https://doi.org/10.14503/thij-14-4353
Abstract
Two validated scoring systems for predicting embolic risk, CHADS2 and CHA2DS2-VASc, contribute to optimizing antithrombotic prescription practices in patients who have atrial fibrillation. However, data about anticoagulated patients are sparse. We compared CHADS2 and CHA2DS2-VASc, in terms of their predictive risk evaluation, in patients with atrial fibrillation who were and were not taking anticoagulants. We systematically searched the Cochrane Library, PubMed, and Embase databases for studies of the comparative diagnostic performance of CHADS2 and CHA2DS2-VASc. We identified 12 cohort studies for meta-analysis. With regard to the occurrence of cardiovascular events individually, patients with CHA2DS2-VASc scores ≥2 have a greater risk of stroke (risk ratio [RR]=5.15; 95% confidence interval [CI], 3.85–6.88; P <0.00001) and thromboembolism (RR=5.96; 95% CI, 5.50–6.45; P <0.00001) (Pdiff=0.34) than do patients with CHA2DS2-VASc scores <2, independent of anticoagulation therapy (RR=5.76; 95% CI, 5.23–6.35; P <0.00001 in anticoagulated patients; and RR=6.12; 95% CI, 5.40–6.93; P <0.00001 in patients not taking anticoagulants; Pdiff=0.45). The pooled RR estimates indicate an approximate 6-fold increase in the risk of endpoint events in patients with CHA2DS2-VASc scores ≥2 (RR=5.90; 95% CI, 5.46–6.37; P <0.0001). These results clearly indicate the discriminative capacity of the CHA2DS2-VASc score for stroke, thromboembolic events, or both, independent of optimal anticoagulation. The CHA2DS2-VASc score enables the identification of patients who are at genuinely high risk and can direct the selection of appropriate therapeutic approaches.Keywords
This publication has 29 references indexed in Scilit:
- CHA2DS2-VASc versus CHADS2 for stroke risk assessment in low-risk patients with atrial fibrillation: a pilot study from a single center of the NCDR-PINNACLE registryJournal of Thrombosis and Thrombolysis, 2013
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillationEP Europace, 2012
- Association of Left Atrial Fibrosis Detected by Delayed-Enhancement Magnetic Resonance Imaging and the Risk of Stroke in Patients With Atrial FibrillationJournal of the American College of Cardiology, 2011
- Stroke Risk Stratification in a “Real-World” Elderly Anticoagulated Atrial Fibrillation PopulationJournal of Cardiovascular Electrophysiology, 2011
- Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort studyThrombosis and Haemostasis, 2011
- Identifying Patients at High Risk for Stroke Despite AnticoagulationStroke, 2010
- A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practiceJournal of Thrombosis and Haemostasis, 2010
- Improving Stroke Risk Stratification in Atrial FibrillationAmerican Journal Of Medicine, 2010
- Validation of Clinical Classification Schemes for Predicting StrokeJAMA, 2001
- Published by Test accounts